Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.33 EUR
Change Today +0.002 / 0.09%
Volume 527.9K
PA8 On Other Exchanges
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

paion ag (PA8) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/14 - €3.64
52 Week Low
10/10/14 - €1.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PAION AG (PA8)

Related News

No related news articles were found.

paion ag (PA8) Related Businessweek News

No Related Businessweek News Found

paion ag (PA8) Details

PAION AG, together with its subsidiaries, operates as a biopharmaceutical company that develops and commercializes drug candidates for diseases or interventions. The company’s portfolio of drug candidates include Remimazolam, a short-acting general anaesthetic/sedative agent that is in Phase-III clinical trials for the treatment of anaesthesia and procedural sedation, as well as in Phase-II clinical trials for ICU sedation. Its drug candidates also comprise Solulin, a variant of the human protein thrombomodulin in Phase-I clinical trials to stabilize the initial fibrin clot to stop bleeding; PN 13, a thrombomodulin mutant in preclinical stage to treat haemophilia and hyperfibrinolysis; and GGF2, a glial growth factor 2 that has completed Phase-I clinical trials to stimulate the growth and differentiation of various cells, including glial cells to demyelinate diseases, such as multiple sclerosis, damage of the myelin sheath, and degeneration of nerve cells. The company was founded in 2000 and is headquartered in Aachen, Germany.

21 Employees
Last Reported Date: 03/18/15
Founded in 2000

paion ag (PA8) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €370.0K
Co-Founder, Chief Medical Officer and Member ...
Total Annual Compensation: €340.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €50.0K
Compensation as of Fiscal Year 2014.

paion ag (PA8) Key Developments

Paion AG Reports Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Paion AG reported consolidated earnings results for the year ended December 31, 2014. In 2014, according to International Financial Reporting Standards (IFRS), revenues amounted to EUR 3.5 million and thus were EUR 0.8 million lower compared to 2013. The financial year 2014 closed with a net loss of EUR 9.1 million, thus exceeding the net loss of EUR 2.2 million of 2013 substantially but according to plan, due to higher research & development (R&D) expenses for the sedative Remimazolam and higher general and administrative costs. Loss per diluted share was EUR 0.23 compared to EUR 0.09 in 2013. Cash flows used in operating activities was EUR 12,044,000 compared to EUR 1,746,000 a year ago. Pretax loss widened to EUR 11.5 million from EUR 3 million a year earlier. For the 2015, the company it does not expect revenues. The net loss will expand to around EUR 25 million to EUR 29 million on higher R&D expenses of EUR 25 million to EUR 30 million and higher general administrative and selling expenses of EUR 4.5 million to EUR 5 million.

Paion AG, 2014 Earnings Call, Mar 18, 2015

Paion AG, 2014 Earnings Call, Mar 18, 2015

Paion AG Presents at 27th Annual ROTH Conference, Mar-11-2015 10:30 AM

Paion AG Presents at 27th Annual ROTH Conference, Mar-11-2015 10:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PA8:GR €2.33 EUR +0.002

PA8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PA8.
View Industry Companies

Industry Analysis


Industry Average

Valuation PA8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.0x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAION AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at